Patients with adult incontinence as a result of multiple sclerosis (MS) or spinal cord injury may soon be able to benefit from Botox therapy.

Healthcare company Allergan has revealed that the treatment received a positive opinion in 14 European countries.

This takes it a step closer towards securing licences for these 14 countries so that people with urinary incontinence due to neurogenic detrusor overactivity may benefit.

Douglas Ingram, president of Allergan in Europe, Africa and the Middle East, said he was pleased with the decision.

He revealed: "For many people with spinal cord injury or multiple sclerosis, gaining effective control over their bladder and staying dry can be a significant step towards improving daily functioning and overall quality of life.

"Our task now is to work closely with the national health authorities to secure the relevant national licences so that we can bring this valuable treatment option to patients, as quickly as possible."

Between 60 and 80 per cent of people with MS experience urinary incontinence or another form of bladder dysfunction, along with 75 to 80 per cent of people with spinal cord injury.

Research has shown that injections of Botox into the bladder muscle can reduce involuntary contractions and reduce patients' reliance on incontinence pants and pads.